Trial · NCT02713828
Adverse events47
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 47
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Metabolism and nutrition disorders Dehydration | Metabolism and nutrition disorders | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Dry mouth | Gastrointestinal disorders | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Dysgeusia | Nervous system disorders | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Neutropenia | Blood and lymphatic system disorders | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Rash papular | Skin and subcutaneous tissue disorders | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Alanine aminotransferase increased | Investigations | Phase I: Glembatumumab Vedotin | 2 | 13 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase I: Glembatumumab Vedotin | 2 | 13 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Aspartate aminotransferase increased | Investigations | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Candida infection | Infections and infestations | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Decreased appetite | Metabolism and nutrition disorders | Phase I: Glembatumumab Vedotin | 3 | 13 | |
| other | Diarrhoea | Gastrointestinal disorders | Phase I: Glembatumumab Vedotin | 2 | 13 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Erythema | Skin and subcutaneous tissue disorders | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Eye pain | Eye disorders | Phase I: Glembatumumab Vedotin | 1 | 13 | |
| other | Fatigue | General disorders | Phase I: Glembatumumab Vedotin | 3 | 13 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02713828/events